Pavurutamab
Based on 1 publication(s) in Google Scholar
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM).
For research use only. We do not sell to patients.
- Purity: 99.9%
- CAS No.: 2250292-39-6
- Molecular Weight:105.78 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Pavurutamab
More
Biological Activity
(scFv-heavy-kappa)-(scFv-heavy-lambda)-scFc
Human
CD3E & TNFRSF17
Pavurutamab (0.005, 0.05 and 0.5 mg/kg; i.v.; every 5 days for 6 administrations, lasting for 30 days) reduces tumor volume and increases survival with time and dose dependent manner in NOD/SCID mice transplanted with L-363 multiple myeloma (MM) cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female NOD/SCID mice transplanted with NCI-H929 MM cells mixed with PBMCs[5].
-
Dosage:0.02, 0.2 and 2 mg/kg.
-
Administration:Intravenous injection; single dose on days 3, 8, 13.
-
Result:Reduced tumor volume.
-
Animal Model:NOD/SCID mice orthotopically transplanted with L-363 MM cells[5].
-
Dosage:0.005, 0.05 and 0.5 mg/kg.
-
Administration:Intravenous injection; every 5 days for 6 administrations, starting from day 9 and lasting for 30 days.
-
Result:Reduced tumor volume and increased survival.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
(scFv-heavy-kappa)-(scFv-heavy-lambda)-scFc
ELISA, FACS, Functional assay
-
Immobilized Pavurutamab can bind Human CD3 epsilon/CD3e Protein (ECD, His Tag). The EC50 for this effect is 1.26 ng/mL. -
Immobilized Pavurutamab can bind Human BCMA Protein (ECD, His Tag). The EC50 for this effect is 0.194 ng/mL. -
Flow cytometric analysis of 1×106 Jurkat cells labelling CD3E (red) with Pavurutamab (HY-P99814). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.
Chemical Information
-
CAS No. 2250292-39-6
-
Appearance Liquid
-
Molecular Weight 105.78 kDa
-
Color Colorless to light yellow
-
SMILES
[Pavurutamab]
-
Synonyms
AMG-701
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
bioRxiv
Transcription Factor Subtype Governs Response and Resistance to DLL3-Directed T-Cell Engagement in Small Cell Lung Cancer. [Abstract]2026 Apr 8:2026.04.02.715020. PMID: 41993528
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Sheridan C. Bispecific antibodies poised to deliver wave of cancer therapies. Nat Biotechnol. 2021 Mar;39(3):251-254. [Content Brief]
[2]. Goldsmith SR, et al. Bispecific Antibodies for the Treatment of Multiple Myeloma. Curr Hematol Malig Rep. 2022 Dec;17(6):286-297. [Content Brief]
[3]. Cho SF, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 Sep 8;4(17):4195-4207. [Content Brief]
[5]. Goldstein RL, et al. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020 Sep 8;4(17):4180-4194. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)